BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/11/2025 1:10:34 PM | Browse: 38 | Download: 0
Publication Name World Journal of Transplantation
Manuscript ID 108982
Country Italy
Category Health Care Sciences & Services
Manuscript Type Review
Article Title Obinutuzumab in kidney transplantation: Past, present, and future
Manuscript Source Invited Manuscript
All Author List Evaldo Favi and Marika Morabito
Funding Agency and Grant Number
Corresponding Author Evaldo Favi, MD, PhD, Department of General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza No. 28, Milan 20122, Lombardy, Italy. evaldofavi@gmail.com
Key Words Obinutuzumab; Rituximab; Kidney transplantation; Desensitization; Antibody-mediated rejection; Glomerulopathies; Recurrence; Review
Core Tip Antibody-mediated rejection and recurrent primary renal diseases remain major causes of kidney transplant loss. Obinutuzumab (OBI) is a type 2 anti-CD20 monoclonal antibody with enhanced peripheral and central B-cell depletion capacities compared to type 1 anti-CD20 monoclonal antibodies. Compared to other B-cell-targeted agents, OBI-induced B-cell depletion is marginally affected by complement function, primarily operating through antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis, and direct cell death. These characteristics suggest that OBI might represent a game-changer in the management of highly sensitized transplant candidates, humoral rejection, and relapsing renal diseases. This review summarizes the current knowledge on OBI use in kidney transplantation.
Citation Favi E, Morabito M. Obinutuzumab in kidney transplantation: Past, present, and future. World J Transplant 2025; In press
Received
2025-04-27 05:39
Peer-Review Started
2025-04-27 05:39
To Make the First Decision
Return for Revision
2025-05-12 04:19
Revised
2025-05-26 08:02
Second Decision
2025-08-11 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-08-11 13:10
Articles in Press
2025-08-11 13:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2220-3230 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com